Kalymin 60 N

Pyridostigmine bromide, the active ingredient in Kalymin 60 N, is a cholinesterase inhibitor presented as an oral dosage form for oral use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel function after surgery.

GNH USA supplies Kalymin 60 N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. With a focus on reliable supply chains, GNH USA ensures product integrity from manufacturing to end‑user.

Pyridostigmine bromide is used to manage conditions that involve impaired neuromuscular transmission.

Myasthenia gravis: enhances skeletal muscle strength by increasing acetylcholine availability. Postoperative ileus: promotes return of intestinal motility after abdominal surgery. Myasthenic crisis: provides symptomatic relief during acute exacerbations of myasthenia gravis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation - Sweating - Muscle cramps

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bradycardia - Bronchospasm - Allergic reactions (rash, angioedema) - Seizures

Careful assessment and monitoring are required before and during therapy. - Renal impairment: adjust dose based on renal function. - Asthma or COPD: monitor for bronchospasm. - Cardiac conduction disorders: observe heart rate and rhythm. - Concomitant anticholinergic drugs: avoid or adjust therapy. - Pregnancy and breastfeeding: safety not established; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pyridostigmine bromide may interact with several drug classes.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine, scopolamine) – may negate therapeutic effect. - Other cholinesterase inhibitors – risk of excessive cholinergic activity.

Moderate Interactions (Monitor Closely): - Beta‑blockers – may exacerbate bradycardia. - Magnesium salts – can potentiate neuromuscular blockade. - Fluoroquinolone antibiotics – may increase risk of tendon toxicity. - Diuretics – monitor electrolyte balance.